Voxelotor treatment of a patient with sickle cell disease and very severe anemia

Am J Hematol. 2019 Apr;94(4):E88-E90. doi: 10.1002/ajh.25389. Epub 2019 Jan 8.

Authors

Affiliations

¹ Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
² Laboratory of Chemical Physics, NIDDK National Institutes of Health, Bethesda, Maryland.
³ Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Anemia, Sickle Cell / blood
Anemia, Sickle Cell / drug therapy*
Anemia, Sickle Cell / pathology
Benzaldehydes / administration & dosage*
Female
Humans
Pyrazines / administration & dosage*
Pyrazoles / administration & dosage*
Severity of Illness Index

Substances

Benzaldehydes
Pyrazines
Pyrazoles
voxelotor

Grants and funding